Activated Platelet Preservation Composition and Method
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preserving platelets are limited, as spontaneous activation during storage leads to aggregation, degradation into microparticles, and a short storage life, making it difficult to maintain activated platelets expressing specific markers like CD61 and CD62p without expressing PAC-1 for an extended period.
Innovation Solution
A composition comprising a divalent cation, chloride, vitamin B, and a selenium source, along with a solvent, is used to preserve activated platelets, maintaining their CD61 and CD62p positivity while inhibiting PAC-1 expression, thereby preventing destruction and extending storage life.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If platelets are preserved using conventional methods, then platelet count is maintained initially, but spontaneous activation occurs leading to aggregation and degradation into microparticles, reducing storage life to only 3-4 days
Solution Approach 1:
The patent applies parameter changes by modifying the chemical composition of the preservation medium to include specific concentrations of divalent cations (Ca2+, Mg2+), chloride ions, vitamin B complex, and a selenium source. These parameter changes in the preservation environment prevent spontaneous activation and maintain platelet integrity throughout the extended storage period of 14 days or longer
Solution Approach 2:
The invention uses a composite preservation composition containing multiple components working synergistically: divalent cations for membrane stability, chloride ions for osmotic balance, vitamin B for metabolic support, and selenium source for antioxidant protection. This composite material approach addresses multiple degradation mechanisms simultaneously, extending storage life while maintaining platelet reliability
2Reliability
If platelets are activated to express CD61 and CD62p markers, then therapeutic potential is improved, but PAC-1 expression occurs leading to aggregation and destruction
Solution Approach 1:
The patent applies local quality by creating a preservation environment that selectively maintains specific platelet markers while suppressing others. The composition enables localized expression of CD61 and CD62p (granule activation markers indicating therapeutic activity) while preventing PAC-1 expression (aggregation marker), achieving differentiated marker control through optimized chemical conditions
Solution Approach 2:
The invention uses partial action by inducing only the necessary level of platelet activation required for therapeutic functionality (CD61 and CD62p expression) without exceeding the threshold that triggers harmful aggregation pathways (PAC-1 expression). The preservation composition carefully controls the activation state to be sufficient for therapy but not excessive enough to cause destruction
Data Source
AI summary
Embodiments relate to an activated platelet preservation composition, a method for preserving activated platelet, and a preserved activated platelet using the same. According to at least one embodiment, there is provided an activated platelet preservation composition including a divalent cation, chloride, vitamin B, a selenium source and a solvent, a kit using the same, a method for preserving an activated platelet, and a preserved activated platelet using the same. According to various embodiments, it is possible to obtain and preserve platelets, which are positive for CD61 and CD62p and negative for PAC-1 among cell markers.